Lon S Schneider
Works at
University of Southern California
Professor
Sources: reporter.nih.gov
Grants and prizes
R01, FDA approved IND 29644: Multicenter Phase 1 Trial to Evaluate Safety and Immunogenicity of Preventive Tau Vaccine, AV-1980R/A, in cognitively unimpaired preclinical AD participants., R01AG092949, 2025–2030, 25 Aug 2026
R01, Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA., R01AG074983, 2022–2027, 30 Jan 2026
R01, Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial, R01AG063826, 2019–2027, 11 Jul 2025
R01, (-)-Phenserine inhibition of neuronal death in Alzheimer’s disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trial, R01AG062687, 2019–2025, 7 Aug 2023
Sources: reporter.nih.gov